NRIX (Nurix Therapeutics) Operating Margin %: -1,041.73% (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NRIX Nurix Therapeutics Inc NRIX
61 GF Score
Price $25.22
GF Value $6.41
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Nurix Therapeutics Operating Margin %?

Nurix Therapeutics NRIX +0.36% 61 Operating Margin % is -1,041.73% as of May. 2026. GuruFocus rates NRIX with a GF Score™ of 61/100 and a GF Value™ of $6.41 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 942 Biotechnology companies, Nurix Therapeutics ranks worse than 78.56% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Nurix Therapeutics's Operating Income for the three months ended in May. 2026 was $-94.20 Mil. Nurix Therapeutics's Revenue for the three months ended in May. 2026 was $9.04 Mil. Therefore, Nurix Therapeutics's Operating Margin % for the quarter that ended in May. 2026 was -1,041.73%.

Good Sign:

Nurix Therapeutics Inc operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Nurix Therapeutics's Operating Margin % or its related term are showing as below:

NRIX' s Operating Margin % Range Over the Past 10 Years
Min: -982.37   Med: -352.41   Max: -26.01
Current: -982.37


NRIX's Operating Margin % is ranked worse than
78.56% of 942 companies
in the Biotechnology industry
Industry Median: -86.06 vs NRIX: -982.37

Nurix Therapeutics's 5-Year Average Operating Margin % Growth Rate was 3.50% per year.

Nurix Therapeutics's Operating Income for the three months ended in May. 2026 was $-94.20 Mil. Its Operating Income for the trailing twelve months (TTM) ended in May. 2026 was $-361.18 Mil.


Nurix Therapeutics  (NAS:NRIX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Nurix Therapeutics Operating Margin % Related Terms


Nurix Therapeutics Operating Margin % Historical Data

* Premium members only.

The historical data trend for Nurix Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nurix Therapeutics Operating Margin % Chart

Nurix Therapeutics Annual Data
Trend Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
Operating Margin %
Get a 7-Day Free Trial -396.26 -476.01 -201.41 -390.52 -340.16

Nurix Therapeutics Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -109.68 -1,157.65 -612.03 -1,479.45 -1,041.73

NRIX vs PHVS, NKTR, TRVI: Operating Margin % Comparison

For the Biotechnology subindustry, Nurix Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nurix Therapeutics Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nurix Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Nurix Therapeutics's Operating Margin % falls into.


NRIX
61GF Score
Nurix Therapeutics Inc NRIX
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nurix Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Nurix Therapeutics's Operating Margin % for the fiscal year that ended in Nov. 2025 is calculated as

Operating Margin %=Operating Income (A: Nov. 2025 ) / Revenue (A: Nov. 2025 )
=-285.666 / 83.98
=-340.16 %

Nurix Therapeutics's Operating Margin % for the quarter that ended in May. 2026 is calculated as

Operating Margin %=Operating Income (Q: May. 2026 ) / Revenue (Q: May. 2026 )
=-94.204 / 9.043
=-1,041.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -1,041.73% mean?
Nurix Therapeutics (NRIX) has a Operating Margin % of -1,041.73% as of May. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Nurix Therapeutics and its competitors. According to the industry distribution chart, Nurix Therapeutics ranks #740 out of 942 companies in the Biotechnology industry, placing it in the top 78.6%.
Is Nurix Therapeutics' Operating Margin % too high?
Nurix Therapeutics' current Operating Margin % is -1,041.73%. Based on the distribution chart, Nurix Therapeutics ranks #740 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nurix Therapeutics has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nurix Therapeutics' Operating Margin % compare to PHVS and NKTR?
According to the Biotechnology industry distribution chart, Nurix Therapeutics ranks #740 out of 942 companies for Operating Margin %. This places Nurix Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Nurix Therapeutics and its competitors. Nurix Therapeutics's current Operating Margin % is -1,041.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nurix Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nurix Therapeutics (NRIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.41, compared to a current price of $25.22 — trading 293.4% above its estimated fair value. The current Operating Margin % is -1,041.73%. Nurix Therapeutics' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Nurix Therapeutics (NRIX), the current Operating Margin % is -1,041.73% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nurix Therapeutics (NRIX) Overvalued in 2026?

Based on GuruFocus' analysis, Nurix Therapeutics stock appears to be overvalued. The current stock price of $25.22 is trading 293.4% above its estimated GF Value™ of $6.41. GuruFocus considers Nurix Therapeutics to be Significantly Overvalued.

Key valuation signals for NRIX:

  • Operating Margin %: -1,041.73%
  • GF Value™: $6.41 vs. price of $25.22 (293.4% above fair value)
  • GF Score™: 61/100 with 6 warning signs

No single metric tells the full story. See the NRIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nurix Therapeutics Business Description

Address 1600 Sierra Point Parkway, Brisbane, CA, USA, 94005
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
61GF Score

Get the complete analysis for NRIX

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.22
Price
$6.41
GF Value